Skip to main content

Table 4 Factors associated with high warfarin dosage in patients administered warfarin at Korle-bu Teaching Hospital in Accra

From: Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population

Characteristic Dosage classification Crude OR [95% CI] p value Adjusted OR [95% CI]a p value
High Low
N = 57 N = 84
n,  % n,  %
Age (years) (median, interquartile range) 46 (33.0–57.0) 48 (36.8–59.0) 0.99 [0.96–1.01] 0.298 0.99 [0.96–1.03] 0.770
Warfarin duration (months) (median, interquartile range) 24 (11–99) 24 (8–61) 1.00 [1.00–1.01] 0.062 1.01 [1.00–1.02] 0.033
Gender
 Female 33 (57.9) 46 (54.8) 1.14 [0.58–2.24] 0.713 1.05 [0.40–2.71] 0.928
 Male 24 (42.1) 38 (45.2) 1.00    
Body mass index
 Overweight 33 (57.9) 53 (63.1) 0.80 [0.40–1.60] 0.535
 Normal 24 (42.1) 31 (36.9) 1.00    
Diagnosis
 Deep vein thrombosis 21 (936.8) 30 (36.2) 1.00 [0.47–2.11] 0.992
 Atrial fibrillation 2 (3.5) 8 (9.6) 0.36 [0.07–1.81] 0.214
 Pulmonary embolism 8 (14.1) 8 (9.6) 1.42 [0.47–4.28] 0.530
 Mistral valve replacement 26 (45.6) 37 (44.6) 1.00    
Presence of side effects
 Yes 11 (19.3) 16 (19.1) 1.02 [0.43–2.39] 0.970
 No 46 (80.7) 68 (80.9) 1.00    
Other medications given
 Yes 30 (52.6) 46 (54.8) 0.92 [0.47–1.80] 0.803
 No 27 (47.4) 38 (45.2) 1.00    
VKORC1
 GA (heterozygous) 1 (2.6) 11 (19.0) 0.12 [0.01–0.94] 0.043 0.06 [0.01–0.63] 0.019
 GG (Wild type) 37 (97.4) 47 (81.0) 1.00   1.00  
CYP4F2
 TT (mutant) 5 (9.6) 3 (4.7) 3 [0.59–15.26] 0.186 5.47 [0.61–48.79] 0.128
 CT (heterozygous) 37 (71.2) 43 (67.2) 1.55 [0.64–3.77] 0.335 1.91 [0.54–6.80] 0.317
 CC (wild type) 10 (19.2) 18 (28.1) 1.00   1.00  
  1. OR odds ratio, CI confidence interval
  2. aVariables with p value <0.02 were entered into the multivariate model in addition to the gene variants VKORC1 and CYP4F2, age, gender and duration on warfarin medication